Ilise Lombardo, MD

Dr. Lombardo is Chief Executive Officer of Noema Pharma AG. She is a seasoned biopharma executive with more than 25 years of experience in the CNS space, spanning clinical practice, academic research, large pharma and biotech. She joined Noema Pharma’s Board of Directors in 2021.

In 2019, Dr Lombardo co-founded Arvelle Therapeutics where she served as Chief Medical Officer. Dr. Lombardo was instrumental in building Arvelle into a launch-ready European CNS company, which was acquired by Angelini Pharma in 2021 for approximately $1 billion. Prior to joining Noema Pharma, Dr. Lombardo was President of the Therapeutics Division at gene therapy company Kriya Therapeutics. Dr. Lombardo has also held senior roles in clinical and medical development at Pfizer, Forum Pharmaceuticals and Axovant Sciences. She was previously on the faculty of Columbia University College of Physicians and Surgeons.

Dr. Lombardo completed two fellowships, one in neuroreceptor imaging and one in molecular genetics. She completed her residency in psychiatry at Columbia University, and obtained her medical degree from Yale University, an M. Phil from the University of Cambridge and a bachelor’s degree from Brown University.